Atlas.
Sign inStart free trial
RXRXNASDAQ · US

RECURSION PHARMACEUTICALS, INC.

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
—
Founded
—
IPO Date
—
HQ
Salt Lake City, UT, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$3.67 ▼ 12.6%
Last (1 Jul 2026) · $4
Period High · $4.96
Period Low · $0.00
52W: $3.67 – $6.79

Key Metrics

Share Price
$3.67
+0.0% today
Market Cap
$618M
P / E
—
EV / Revenue
—
Revenue Growth
+26.9%
year-on-year
Gross Margin
—
Enterprise Value
$-115,992,865.85
52W High
$6.79
52W Low
$0.00
Avg Volume
15.9M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
13 known institutional holders·$312M total on record·2026-Q1
BlackRock, Inc.
25.7%·$133M
State Street Corp
16.9%·$87M
Geode Capital Management, LLC
7.3%·$38M
Goldman Sachs Group Inc
3.6%·$19M
Northern Trust Corp
2.4%·$12M
Bank Of America Corp
1.5%·$8M
Renaissance Technologies LLC
1.4%·$7M
Jpmorgan Chase & Co
0.8%·$4M
Fmr LLC
0.4%·$2M
Invesco Ltd.
0.4%·$2M
Price T Rowe Associates Inc
0.3%·$1,722
Point72 Asset Management, L.P.
0.0%·$142,141
Dimensional Fund Advisors LP
0.0%·$66,551
Free Float
39.2%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for RECURSION PHARMACEUTICALS, INC.
OverviewRECURSION PHARMACEUTICALS, INC. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow RECURSION PHARMACEUTICALS, INC. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsRECURSION PHARMACEUTICALS, INC.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityRECURSION PHARMACEUTICALS, INC. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsRECURSION PHARMACEUTICALS, INC.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for RECURSION PHARMACEUTICALS, INC., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for RECURSION PHARMACEUTICALS, INC. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersRECURSION PHARMACEUTICALS, INC. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for RECURSION PHARMACEUTICALS, INC. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for RECURSION PHARMACEUTICALS, INC. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial